Side-by-side IPO readiness, funding history, and valuation comparison. Data sourced by TechStackIPO.
Scores, valuations, and signals for Nimbus Therapeutics, Shein, and 370+ companies. 5-min read every Tuesday.
Nimbus Therapeutics uses structure-based drug design and computational tools to develop precision medicines for challenging targets including NASH, oncology, and immunology. Valued at $2B with $500M raised, Nimbus has multiple clinical-stage programs and partnerships with Takeda and Eli Lilly. Major healthtech IPO candidate as computational drug design matures into commercial medicine.
| Industry | Biotechnology |
| Stage | Late Stage Private |
| IPO Status | Private |
| Valuation | $2B |
| Total Funding | $637M |
| Headquarters | Cambridge, MA |
Shein is the world's largest fast fashion company, valued at $66B with $5.2B raised. Track IPO readiness score, funding history, and public market timeline.
| Industry | E-Commerce |
| Stage | Pre-IPO |
| IPO Status | Pre-IPO |
| Valuation | $30-50B |
| Total Funding | $5.2B |
| Headquarters | Singapore |
Complete funding history, cap table, S-1 analysis, and investor breakdown for any company. Instant PDF download.
Or buy any single company report for $19
Nimbus Therapeutics is valued at $2B. Shein is valued at $30-50B. Both figures are based on the most recent funding rounds tracked by TechStackIPO.
Nimbus Therapeutics is currently private. Shein filed an S-1 in June 2024 and is actively in the IPO pipeline. Track both companies on TechStackIPO for S-1 filings, roadshow announcements, and IPO date updates.
Nimbus Therapeutics has raised $637M. Shein has raised $5.2B.
Nimbus Therapeutics operates in Biotechnology, while Shein operates in E-Commerce.
Nimbus Therapeutics is a Biotechnology company valued at $2B with $637M raised. Shein is a E-Commerce company valued at $30-50B with $5.2B raised. See TechStackIPO's full side-by-side comparison for IPO readiness scores, funding timelines, and investor access options.
Accredited investors can access pre-IPO shares in Nimbus Therapeutics and Shein through secondary market platforms, pre-IPO funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace section tracks available access options for both companies. Pre-IPO investments carry higher risk and limited liquidity.